English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA combination treatment that targets the immune system helps treat aggressive prostate cancers that don’t respond to conventional therapies.
Tag: metastatic castrate-resistant prostate cancer
Researchers uncover a way to harness the power of immunotherapy for advanced prostate cancer
Researchers led by the University of Michigan Rogel Cancer Center identified an inhibitor that showed promise against metastatic castration-resistant prostate cancer cells.
BET inhibitors show promise in overcoming lineage plasticity, a newly recognized form of resistance to prostate cancer drugs
In a new study, a team of researchers uncovered new mechanisms underlying an important type of resistance to modern prostate cancer drugs called lineage plasticity, where castration-resistant prostate cancers undergo a deadly identity switch. They also outline a promising path to overcoming this form of resistance: BET bromodomain inhibitors.